Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Takács F, Kotmayer L, Czeti Á, Szalóki G, László T, Mikala G, Márk Á, Masszi A, Farkas P, Plander M, Weisinger J, Demeter J, Fekete S, Szerafin L, Deák BM, Szaleczky E, Sulák A, Borbényi Z, Barna G. Takács F, et al. Among authors: demeter j. Pathol Oncol Res. 2022 Sep 21;28:1610659. doi: 10.3389/pore.2022.1610659. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36213161 Free PMC article.
Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D. Bödör C, et al. Among authors: demeter j. Br J Haematol. 2021 Jul;194(2):355-364. doi: 10.1111/bjh.17502. Epub 2021 May 21. Br J Haematol. 2021. PMID: 34019713
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.
Varga G, Nagy Z, Demeter J, Kosztolányi S, Szomor Á, Alizadeh H, Deák B, Schneider T, Plander M, Szendrei T, Váróczy L, Illés Á, Bátai Á, Pető M, Mikala G. Varga G, et al. Among authors: demeter j. Pathol Oncol Res. 2019 Oct;25(4):1615-1620. doi: 10.1007/s12253-019-00607-2. Epub 2019 Feb 2. Pathol Oncol Res. 2019. PMID: 30712192 Free PMC article.
[TP53 mutation analysis in chronic lymphocytic leukaemia].
Fésüs V, Marosvári D, Kajtár B, Király PA, Demeter J, Gurbity Pálfi T, Egyed M, Plander M, Farkas P, Mátrai Z, Matolcsy A, Bödör C. Fésüs V, et al. Among authors: demeter j. Orv Hetil. 2017 Feb;158(6):220-228. doi: 10.1556/650.2017.30656. Orv Hetil. 2017. PMID: 28166664 Hungarian.
Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T, Rosta A, Losonczy H, Radványi G, Ujj G, Egyed M, Illés Á, Jakucs J, Szerafin L, Gasztonyi Z, Masszi T, Iványi J, Demeter J, Dombi P, Tóth A, Borbényi Z. Schneider T, et al. Among authors: demeter j. Pathol Oncol Res. 2018 Apr;24(2):199-205. doi: 10.1007/s12253-017-0234-2. Epub 2017 Apr 21. Pathol Oncol Res. 2018. PMID: 28432650 Free article. Clinical Trial.
258 results